Published in Electrophoresis on July 01, 2007
Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol (2012) 3.48
Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev (2009) 3.08
Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci (2013) 1.16
Tissue distribution and pharmacokinetics of stable polyacrylamide nanoparticles following intravenous injection in the rat. Toxicol Appl Pharmacol (2010) 1.02
Protein adsorption is required for stealth effect of poly(ethylene glycol)- and poly(phosphoester)-coated nanocarriers. Nat Nanotechnol (2016) 1.01
Evaluation of anticancer activity of celastrol liposomes in prostate cancer cells. J Microencapsul (2014) 0.92
Cellular Binding of Anionic Nanoparticles is Inhibited by Serum Proteins Independent of Nanoparticle Composition. Biomater Sci (2013) 0.91
The nano-plasma interface: Implications of the protein corona. Colloids Surf B Biointerfaces (2014) 0.90
Influence of polyethylene glycol density and surface lipid on pharmacokinetics and biodistribution of lipid-calcium-phosphate nanoparticles. Biomaterials (2014) 0.89
Human plasma protein adsorption onto dextranized surfaces: a two-dimensional electrophoresis and mass spectrometry study. Colloids Surf B Biointerfaces (2011) 0.88
Shrinkage of pegylated and non-pegylated liposomes in serum. Colloids Surf B Biointerfaces (2013) 0.86
Analytical strategies for detecting nanoparticle-protein interactions. Analyst (2010) 0.85
Safety of Nanoparticles in Medicine. Curr Drug Targets (2015) 0.83
Protein corona - from molecular adsorption to physiological complexity. Beilstein J Nanotechnol (2015) 0.82
Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities. Adv Drug Deliv Rev (2015) 0.79
Protein Adsorption Patterns and Analysis on IV Nanoemulsions-The Key Factor Determining the Organ Distribution. Pharmaceutics (2012) 0.78
Quantitative analysis of nanoparticle transport through in vitro blood-brain barrier models. Tissue Barriers (2016) 0.75
BSA modification to reduce CTAB induced nonspecificity and cytotoxicity of aptamer-conjugated gold nanorods. Nanoscale (2015) 0.75
Interaction of gold nanoparticles with proteins and cells. Sci Technol Adv Mater (2015) 0.75
Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev (2002) 7.05
Stimuli-responsive nanocarriers for drug delivery. Nat Mater (2013) 3.52
Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci (2009) 2.63
Porous metal-organic-framework nanoscale carriers as a potential platform for drug delivery and imaging. Nat Mater (2009) 2.43
Magnetic nanoparticles: design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications. Chem Rev (2012) 2.26
Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physicochemical characterization, and in vitro experiments. Bioconjug Chem (2005) 1.99
Metal-organic frameworks in biomedicine. Chem Rev (2011) 1.93
Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem Soc Rev (2013) 1.43
Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J Hepatol (2005) 1.38
Squalenoyl nanomedicines as potential therapeutics. Nano Lett (2006) 1.28
Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Deliv Rev (2003) 1.25
Squalene: A natural triterpene for use in disease management and therapy. Adv Drug Deliv Rev (2009) 1.25
Physicochemical characterization of ultrasmall superparamagnetic iron oxide particles (USPIO) for biomedical application as MRI contrast agents. Int J Nanomedicine (2007) 1.21
Nanotheranostics for personalized medicine. Adv Drug Deliv Rev (2012) 1.19
BioMOFs: metal-organic frameworks for biological and medical applications. Angew Chem Int Ed Engl (2010) 1.16
Surface-engineered nanoparticles for multiple ligand coupling. Biomaterials (2003) 1.15
Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J Pharmacol Exp Ther (2002) 1.12
Influence of polysaccharide coating on the interactions of nanoparticles with biological systems. Biomaterials (2006) 1.12
Polysaccharide-decorated nanoparticles. Eur J Pharm Biopharm (2004) 1.08
A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types. J Control Release (2007) 1.06
Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug Chem (2005) 1.03
Styrylquinolines, integrase inhibitors acting prior to integration: a new mechanism of action for anti-integrase agents. J Virol (2004) 1.02
"Smart" delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. Adv Drug Deliv Rev (2004) 1.01
Metallic colloid nanotechnology, applications in diagnosis and therapeutics. Curr Pharm Des (2005) 1.01
A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. J Neurosci (2009) 1.01
A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity. Proc Natl Acad Sci U S A (2014) 1.00
Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. Nanomedicine (2011) 0.99
Use of self assembled magnetic beads for on-chip protein digestion. Lab Chip (2005) 0.99
Novel approaches to deliver gemcitabine to cancers. Curr Pharm Des (2008) 0.99
Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues. Nanomedicine (2011) 0.98
Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur J Immunol (2004) 0.98
Negative preclinical results with stealth nanospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model. J Control Release (2004) 0.98
Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules. Int J Pharm (2007) 0.98
Lipid conjugated oligonucleotides: a useful strategy for delivery. Bioconjug Chem (2012) 0.97
Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B. Antimicrob Agents Chemother (2003) 0.97
Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma. Pharm Res (2006) 0.96
Magnetoresponsive squalenoyl gemcitabine composite nanoparticles for cancer active targeting. Langmuir (2008) 0.95
Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur J Neurosci (2002) 0.95
Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor. Int J Pharm (2005) 0.95
Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine. J Drug Target (2009) 0.95
Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics. ACS Nano (2011) 0.94
Role of gut macrophages in mice orally contaminated with scrapie or BSE. Int J Pharm (2005) 0.93
Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis. Biomacromolecules (2007) 0.92
New HIV-1 replication inhibitors of the styryquinoline class bearing aroyl/acyl groups at the C-7 position: synthesis and biological activity. Bioorg Med Chem Lett (2005) 0.91
Versatile and efficient targeting using a single nanoparticulate platform: application to cancer and Alzheimer's disease. ACS Nano (2012) 0.91
Investigation of the degradation mechanisms of poly(malic acid) esters in vitro and their related cytotoxicities on J774 macrophages. Biomacromolecules (2004) 0.91
Study of emulsion stabilization by graft copolymers using the optical analyzer Turbiscan. Int J Pharm (2003) 0.90
Self-assembled multicompartment liquid crystalline lipid carriers for protein, peptide, and nucleic acid drug delivery. Acc Chem Res (2010) 0.90
Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Invest Ophthalmol Vis Sci (2002) 0.90
Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma. J Med Chem (2011) 0.90
Colloidal stability of ultrasmall superparamagnetic iron oxide (USPIO) particles with different coatings. Int J Pharm (2006) 0.90
Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine. J Pharmacol Exp Ther (2008) 0.89
Development of a magnetic immunosorbent for on-chip preconcentration of amyloid β isoforms: Representatives of Alzheimer's disease biomarkers. Biomicrofluidics (2012) 0.88
LIF detection of peptides and proteins in CE. Electrophoresis (2007) 0.88
Squalenoylation: a generic platform for nanoparticular drug delivery. J Control Release (2011) 0.88
Novel polysaccharide-decorated poly(isobutyl cyanoacrylate) nanoparticles. Pharm Res (2003) 0.88
Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice. Drug Metab Dispos (2008) 0.88
Discovery of new hexagonal supramolecular nanostructures formed by squalenoylation of an anticancer nucleoside analogue. Small (2008) 0.88
Cationic vectors in ocular drug delivery. J Drug Target (2004) 0.87
Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor. Mol Pharm (2009) 0.87
A methodology to study intracellular distribution of nanoparticles in brain endothelial cells. Int J Pharm (2005) 0.87
PEGylated nanoparticles bind to and alter amyloid-beta peptide conformation: toward engineering of functional nanomedicines for Alzheimer's disease. ACS Nano (2012) 0.86
Carbon nanotube translocation to distant organs after pulmonary exposure: insights from in situ (14)C-radiolabeling and tissue radioimaging. ACS Nano (2014) 0.86
Design of fluorescently tagged poly(alkyl cyanoacrylate) nanoparticles for human brain endothelial cell imaging. Chem Commun (Camb) (2010) 0.86
Novel zwitterionic reverse micelles for encapsulation of proteins in low-viscosity media. Chemistry (2006) 0.86
Mechanistic study of the proangiogenic effect of osteoprotegerin. Angiogenesis (2013) 0.85
Extensive surface studies help to analyse zeta potential data: the case of cationic emulsions. Chem Phys Lipids (2004) 0.85
Determination of binding constants of hydrophobically end-capped poly(ethylene glycol)s with beta-cyclodextrin by affinity capillary electrophoresis. J Chromatogr A (2004) 0.85
Poly(lactide-co-glycolide) microspheres for the controlled release of oligonucleotide/polyethylenimine complexes. J Pharm Sci (2002) 0.85
Heparin coated poly(alkylcyanoacrylate) nanoparticles coupled to hemoglobin: a new oxygen carrier. Biomaterials (2004) 0.84
Hybrid polymer nanocapsules enhance in vitro delivery of azidothymidine-triphosphate to macrophages. J Control Release (2006) 0.84
Biological characterization of folic acid-conjugated poly(H2NPEGCA-co-HDCA) nanoparticles in cellular models. J Drug Target (2007) 0.84
Microchip electrophoresis profiling of Aβ peptides in the cerebrospinal fluid of patients with Alzheimer's disease. Anal Chem (2010) 0.84